范可尼贫血诱导多能干细胞模型揭示p53驱动祖细胞分化机制
研究通过可诱导互补FANCA缺陷的诱导多能干细胞(IPSC)模型,在定向分化为造血祖细胞(HPC)时调控FANCA,成功制备重现范可尼贫血(FA)基因毒性和造血表型的FANCA缺陷人类HPC。FANCA缺陷HPC中p53/p21激活驱动终末分化加速,GAS6是活化p53的新靶点,调控GAS6信号可挽救FANCA缺陷细胞的造血。
要点
- 可诱导互补FANCA的IPSC模型可稳定维持并分化为重现FA表型的HPC。
- FANCA缺陷HPC中p53/p21激活导致终末分化加速。
- GAS6是活化p53新靶点,调控其信号可挽救FANCA缺陷细胞造血。
核心结论
- 成功建立可持续、高度忠实的人类FA模型,揭示FA中HPC耗竭由p53/p21驱动终末分化加速的机制,并推进未来FA细胞治疗。
研究设计与样本
- 利用可诱导互补FANCA缺陷的IPSC,在定向分化为HPC时调控FANCA,制备FANCA缺陷人类HPC并与同基因FANCA表达HPC比较。
主要发现
- FANCA缺陷人类HPC重现FA基因毒性和造血表型。
- FANCA缺陷人类HPC中p53/p21激活驱动终末分化加速。
- GAS6被鉴定为FANCA缺陷HPC中活化p53的新靶点,调控GAS6信号可挽救FANCA缺陷细胞造血。
临床怎么用
- 该模型可用于研究FA造血衰竭机制并测试靶向p53/GAS6通路的干预策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fanconi anemia (FA) is a disorder of DNA repair that manifests as bone marrow (BM) failure. The lack of accurate murine models of FA has refocused efforts toward differentiation of patient-derived induced pluripotent stem cells (IPSCs) to hematopoietic progenitor cells (HPCs). However, an intact FA DNA repair pathway is required for efficient IPSC derivation, hindering these efforts. To overcome this barrier, we used inducible complementation of FANCA-deficient IPSCs, which permitted robust maintenance of IPSCs. Modulation of FANCA during directed differentiation to HPCs enabled the production of FANCA-deficient human HPCs that recapitulated FA genotoxicity and hematopoietic phenotypes relative to isogenic FANCA-expressing HPCs. FANCA-deficient human HPCs underwent accelerated terminal differentiation driven by activation of p53/p21. We identified growth arrest specific 6 (GAS6) as a novel target of activated p53 in FANCA-deficient HPCs and modulate GAS6 signaling to rescue hematopoiesis in FANCA-deficient cells. This study validates our strategy to derive a sustainable, highly faithful human model of FA, uncovers a mechanism of HPC exhaustion in FA, and advances toward future cell therapy in FA.
引用
- Marion W, Boettcher S, Ruiz-Torres S, et al. An induced pluripotent stem cell model of Fanconi anemia reveals mechanisms of p53-driven progenitor cell differentiation. Blood Adv. 2020. PMID: 33002135. doi:10.1182/bloodadvances.2020001593
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。